Addressing a press conference Serum Institute of India (SII) Chief Executive Officer (CEO) Adar Poonawalla has said
“As of now we don’t have anything in writing of how many doses the Government of India would purchase, but the indication is 300-400 mn doses by July 2021.”
Poonawalla’s statement comes after PM Narendra Modi on Saturday visited the company’s facility in Pune to check on the development of the Coronavirus vaccine. PM Narendra Modi took a three-city tour to Ahmadabad, Pune, and Hyderabad on Saturday.
- Serum Institute of India (SII) – “Covishield”
- Zydus Cadila – “ZyCoV-D”
- Bharat Biotech International Limited – “Covaxin”
The tour is planned to check on the status of vaccines being developed by three companies and to plan various aspects such as launch, production, costs, and distribution mechanisms.
Poonawala also added, “We are in the process of applying in the next two weeks for the emergency use.” Serum Institute of India has partnered with global pharma giant AstraZeneca and Oxford University for the vaccine candidate ‘Covidshield’.
Regarding the distribution of Covishield
Regarding the distribution of the vaccine, SII Chief added that the company’s first priority is India.
“Vaccine will be distributed initially in India, and then we will look at the COVAX countries which are mainly in Africa. The UK and European markets are being taken care of by AstraZeneca and Oxford. Our priority is India and COVAX countries.”